The Multiple Myeloma Partnering 2010-2015 report provides understanding and access to the multiple myeloma partnering deals and agreements entered into by the worlds leading healthcare companies.
- Trends in multiple myeloma partnering deals
- Top multiple myeloma deals by value
- Deals listed by company A-Z, industry sector, stage of development, technology type
The Multiple myeloma Partnering 2010-2015 provides understanding and access to the multiple myeloma partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides an analysis of multiple myeloma partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors multiple myeloma technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.
This data driven report contains over 90 links to online copies of actual multiple myeloma deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of multiple myeloma partnering trends.
Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in partnering since 2010, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.
Chapter 3 provides an overview of the average deal terms since 2010. The chapter includes deals with a stage of development announced by headline value, upfront value, milestone value and royalty rate.
Chapter 4 provides an overview of the most active dealmakers, top dealmakers by value, active big pharma and big biotech dealmakers including contract documents where available.
Chapter 5 provides a comprehensive directory of partnering deals signed and announced since 2010. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of bladder cancer technologies and products.
Multiple myeloma Partnering 2010-2015 is intended to provide the reader with an in-depth understanding and access to multiple myeloma trends and structure of deals entered into by leading companies worldwide.
This data driven report includes:
- Trends in multiple myeloma dealmaking in the biopharma industry since 2010
- Access to summary headline, upfront, milestone and royalty data
- Access to over 100 multiple myeloma contract documents
- The leading multiple myeloma deals by value since 2010
In Multiple myeloma Partnering 2010-2015, the available deals are listed by:
- Headline value
- Upfront payment value
- Royalty rate value
- Company A-Z
- Industry sector
- Stage of development at signing
- Deal component type
- Technology type
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Table of Content
Chapter 1 – Introduction
Chapter 2 – Trends in multiple myeloma partnering
2.2. Multiple myeloma partnering over the years
2.3. Big pharma multiple myeloma dealmaking activity
2.4. Big biotech multiple myeloma dealmaking activity
2.5. Most active multiple myeloma dealmakers
2.6. Multiple myeloma partnering by deal type
2.7. Multiple myeloma partnering industry sector
2.8. Multiple myeloma partnering by stage of development
2.9. Multiple myeloma partnering by technology type
2.10. Disclosed financial deal terms for multiple myeloma
2.10.1 Multiple myeloma headline values
2.10.2 Multiple myeloma upfront payments
2.10.3 Multiple myeloma milestone payments
2.10.4 Multiple myeloma royalty rates
Chapter 3 – Leading multiple myeloma deals
3.2. Top multiple myeloma deals by value
Chapter 4 – Dealmaking directory
4.2. Company A-Z
4.3. By deal type
4.4. By industry sector
4.5. By stage of development
4.6. By technology type
Chapter 5 – Partnering resource center
5.1. Online partnering
5.2. Partnering events
5.3. Further reading on dealmaking
Appendix 1 – Deal type definitions
About Wildwood Ventures
Recent report titles from Current Partnering
Order Form – Reports
Order Form – Subscription Access Products
List of Chart
Figure 1: Multiple myeloma partnering since 2009
Figure 2: Big pharma – top 50 – multiple myeloma deals 2009 to 2014
Figure 3: Big pharma multiple myeloma deal frequency – 2009 to 2014
Figure 4: Big biotech – top 50 – multiple myeloma deals 2009 to 2014
Figure 5: Big biotech multiple myeloma deal frequency – 2009 to 2014
Figure 6: Multiple myeloma dealmaking activity– 2009 to 2014
Figure 7: Multiple myeloma partnering by deal type since 2009
Figure 8: Multiple myeloma partnering by industry sector since 2009
Figure 9: Multiple myeloma partnering by stage of development since 2009
Figure 10: Multiple myeloma partnering by technology type since 2009
Figure 11: Multiple myeloma deals with a headline value
Figure 12: Multiple myeloma deals with upfront payment values
Figure 13: Multiple myeloma deals with milestone payments
Figure 14: Multiple myeloma deals with royalty rates, %
Figure 15: Top multiple myeloma deals by value since 2009
Figure 16: Online partnering resources
Figure 17: Forthcoming partnering events
Figure 18: Deal type definitions
Make an enquiry before buying this Report
Please fill the enquiry form below.